Series B investment

UK charity Prostate Cancer Research invests in Oxford Vacmedix Series B

Support from leading Prostate cancer charity for the clinical development of OVM-200. Oxford, UK – 27th November 2024 Press Release – Prostate Cancer Research invests in Oxford Vacmedix Series B Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today Series B investment from Proven Connect, the translational arm of the charity Prostate Cancer Research (PCR). ​ Proven Connect bridges the gap between industry, investors, health prov...
Read More
en_GBEnglish